On March 3, 2025, Bioxcel Therapeutics reported that the FDA concluded its inspection of a site in the TRANQUILITY II Phase 3 trial, indicating some objectionable conditions but no regulatory action. Additionally, the company announced the resignation of its Chief of Product Development and Medical Officer on February 28, 2025.